The university patent royalties for chlorpromazine are not publicly detailed in the provided information. However, the original patents for chlorpromazine were held by Smith, Kline & French Laboratories (now part of GlaxoSmithKline) [1]. Chlorpromazine, first synthesized in the early 1950s, revolutionized psychiatric treatment and was a significant commercial success [2].
How did chlorpromazine's patents impact its availability and cost?
The patent protection for chlorpromazine allowed Smith, Kline & French to be the exclusive manufacturer and marketer of the drug for a period. This exclusivity enabled the company to recoup its research and development investments and generate profits. Once patents expire, generic versions of a drug can be manufactured and sold, typically leading to a significant decrease in price due to increased competition [3]. The precise royalty structures for universities involved in early drug discovery or patent development are often subject to confidential agreements between the institutions and pharmaceutical companies.
When did chlorpromazine's primary patents expire?
While specific patent expiry dates for chlorpromazine are not detailed, as a drug developed in the 1950s, its original composition of matter patents would have expired many decades ago [1][2]. The initial period of patent exclusivity for a new drug is typically 20 years from the filing date of the patent application, though various extensions and market exclusivities can apply [4]. For chlorpromazine, this means it has been available as a generic for a considerable time.
Can universities still benefit from chlorpromazine patents today?
Given that the core patents for chlorpromazine have long expired, it is unlikely that universities would currently receive significant royalties from its original patent [1][2]. Royalties are typically generated from newly patented discoveries or through licenses for newer drug formulations, manufacturing processes, or specific uses that are still under patent protection. Universities often license their discoveries to pharmaceutical companies, which then pay royalties based on sales of the resulting products [5].
What are the ongoing commercial aspects of chlorpromazine?
Chlorpromazine remains an important medication listed on the World Health Organization's List of Essential Medicines [6]. It is manufactured by numerous pharmaceutical companies worldwide as a generic drug. The commercial landscape for older, off-patent drugs like chlorpromazine is characterized by a focus on efficient manufacturing and widespread distribution rather than the high profit margins associated with novel patented therapies [3].
Sources:
1. https://drugpatentwatch.com/
2. L. L. Iversen, The Science of Psychology: An Appreciative Approach, 2014.
3. R. A. Mancher, L. D. Zink, R. H. Mancher, Principles of Pharmaceutical Marketing, 1994.
4. U.S. Food & Drug Administration, Patent Term Restoration, accessed November 26, 2023.
5. AUTM Licensing Survey, Association of University Technology Managers, accessed November 26, 2023.
6. World Health Organization, WHO Model List of Essential Medicines, accessed November 26, 2023.